Jay Olson Analyst PerformanceAnalyst at OppenheimerJay Olson is a stock analyst at Oppenheimer focused in the medical sector, covering 47 publicly traded companies. Over the past year, Jay Olson has issued 30 stock ratings, including buy and hold recommendations. While full access to Jay Olson's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jay Olson's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings313 Last 11 YearsBuy Recommendations80.46% 243 Buy RatingsCompanies Covered47 Unique Companies Ratings Distribution302RatingsDistribution of strong buy, buy, hold, and sell ratings by Jay Olson.RatingPercentageCount Strong Buy0.0%0 ratings Buy80.5%243 ratings Hold18.5%56 ratings Sell1.0%3 ratingsOut of 302 total stock ratings issued by Jay Olson at Oppenheimer, the majority (80.5%) have been Buy recommendations, followed by 18.5% Hold and 1.0% Sell.Best & Worst CallsBest Call0000.0%PRTASep 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%CNATOct 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ47 companiesJay Olson, an analyst at Oppenheimer, currently covers 47 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical44 companies93.6%Manufacturing2 companies4.3%Aerospace1 company2.1%Jay Olson of Oppenheimer specializes in stock coverage within the Medical sector, with additional focus on Manufacturing and Aerospace companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE29 companies61.7%MED - DRUGS8 companies17.0%PHARMACEUTICAL PREPARATIONS4 companies8.5%BIOTECHNOLOGY3 companies6.4%Miscellaneous1 company2.1%MED - OUTP/HM CRE1 company2.1%AEROSP/DEF EQ1 company2.1% Jay Olson's Ratings History at Oppenheimer Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsBIIBBiogen5/14/2026Boost Price Target$192.43$300.00Outperform$0.0000.00% ROIINCYIncyte4/29/2026Boost Price Target$97.74$90.00Market Perform$0.0000.00% ROITERNTerns Pharmaceuticals4/27/2026Reiterated Rating$52.91$58.00Market Perform$0.0000.00% ROIPASGPassage Bio4/21/2026Lower Price Target$6.18$15.00Outperform$0.0000.00% ROIBIIBBiogen4/1/2026Boost Price Target$183.33$275.00Outperform$0.0000.00% ROIPASGPassage Bio3/31/2026Initiated Coverage$6.18$30.00Outperform$0.0000.00% ROIBCYCBicycle Therapeutics3/18/2026Lower Price Target$4.83$36.00Outperform$0.0000.00% ROINKTRNektar Therapeutics3/13/2026Reiterated Rating$73.00$140.00Outperform$0.0000.00% ROIVRTXVertex Pharmaceuticals3/10/2026Boost Price Target$460.87$600.00Outperform$0.0000.00% ROIBIOABioAge Labs2/25/2026Initiated Coverage$21.56$60.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. VRTXVertex Pharmaceuticals2/13/2026Upgrade$465.02$540.00Outperform$0.0000.00% ROIACADACADIA Pharmaceuticals2/6/2026Boost Price Target$23.79$23.00Market Perform$0.0000.00% ROIBIIBBiogen1/30/2026Boost Price Target$176.18$225.00Outperform$0.0000.00% ROICHRSCoherus Oncology1/22/2026Initiated Coverage$1.59$10.00Outperform$0.0000.00% ROIAXSMAxsome Therapeutics12/31/2025Reiterated Rating$183.95$220.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines12/15/2025Reiterated Rating$268.80$750.00Outperform$0.0000.00% ROITERNTerns Pharmaceuticals12/9/2025Boost Price Target$40.23$58.00Outperform$0.0000.00% ROIMDGLMadrigal Pharmaceuticals11/20/2025Boost Price Target$555.60$650.00Outperform$0.0000.00% ROITERNTerns Pharmaceuticals11/3/2025Reiterated Rating$14.03$24.00Outperform$0.0000.00% ROIIBIOiBio10/29/2025Reiterated Rating$1.54Outperform$0.0000.00% ROIIBIOiBio10/21/2025Initiated Coverage$0.89$5.00Outperform$0.0000.00% ROIMDGLMadrigal Pharmaceuticals10/10/2025Boost Price Target$428.30$590.00Outperform$0.0000.00% ROIIMRXImmuneering9/25/2025Boost Price Target$8.36$30.00Outperform$0.0000.00% ROIBCYCBicycle Therapeutics8/11/2025Reiterated Rating$7.59$44.00Outperform$0.0000.00% ROIDFTXDefinium Therapeutics8/4/2025Initiated Coverage$8.44$25.00Outperform$0.0000.00% ROIATAIAtai Beckley7/29/2025Initiated Coverage$3.33$14.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines7/8/2025Boost Price Target$46.39$115.00Outperform$0.0000.00% ROIPRAXPraxis Precision Medicines6/2/2025Set Price Target$37.82$97.00Outperform$0.0000.00% ROIPRTAProthena5/27/2025Downgrade$6.58Market Perform$0.0000.00% ROITVRDTvardi Therapeutics5/21/2025Initiated Coverage$29.09$65.00Outperform$0.0000.00% ROIJSPRJasper Therapeutics5/15/2025Lower Price Target$4.88$65.00Outperform$0.0000.00% ROIINOInovio Pharmaceuticals5/14/2025Lower Price Target$1.86$13.00Outperform$0.0000.00% ROIRVMDRevolution Medicines5/8/2025Boost Price Target$42.56$75.00Outperform$000.0000.00% ROIIMRXImmuneering5/7/2025Lower Price Target$1.18$21.00Outperform$0.0000.00% ROIBIIBBiogen5/2/2025Set Price Target$121.80$205.00$000.0000.00% ROINKTRNektar Therapeutics3/14/2025Upgrade$12.23$90.00Outperform$00.0000.00% ROIDNLIDenali Therapeutics3/3/2025Lower Price Target$15.46$42.00Outperform$00.0000.00% ROIPRTAProthena2/7/2025Boost Price Target$13.93$62.00Outperform$0.0000.00% ROIEXELExelixis1/24/2025Downgrade$34.13$33.00Market Perform$00.0000.00% ROIEXELExelixis1/16/2025Boost Price Target$36.81$41.00Outperform$00.0000.00% ROIThe REAL Reason Trump is Invading Iran (Ad)For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.Click here to find out what it is.NTLAIntellia Therapeutics1/13/2025Lower Price Target$9.99$40.00Outperform$00.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock10/17/2024Boost Price Target$6.71$10.00Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWeiss RatingsUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
